{
    "clinical_study": {
        "@rank": "95978", 
        "brief_summary": {
            "textblock": "To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2\n      doses. To gain safety and efficacy data from a broader base of patients with HIV-associated\n      wasting in order to support Celgene's pivotal placebo-controlled study."
        }, 
        "brief_title": "Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome", 
        "condition": [
            "HIV Infections", 
            "HIV Wasting Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Wasting Syndrome", 
                "HIV Wasting Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive thalidomide at 1 of 2 doses for 12 weeks initially, with\n      response assessed at weeks 2, 4, 8, and 12. Patients failing the low dose will be eligible\n      to increase the dose to the higher dose. Treatment may continue indefinitely. After 12\n      weeks, patients continuing treatment are evaluated every 2 months for up to 6 additional\n      months, then every 6 months thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiretroviral therapy.\n\n          -  Prophylaxis or treatment for opportunistic infection.\n\n        Patients must have:\n\n        HIV-associated wasting.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior enrollment on Celgene's placebo-controlled thalidomide study, provided patient\n             meets specified criteria for not continuing on that study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002157", 
            "org_study_id": "230B", 
            "secondary_id": "W-002"
        }, 
        "intervention": {
            "intervention_name": "Thalidomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Thalidomide"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "Cachexia", 
            "Thalidomide"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Warren", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07059"
                }, 
                "name": "Celgene Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002157"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1998"
    }, 
    "geocoordinates": {
        "Celgene Corp": "40.634 -74.5"
    }
}